Cobro Ventures

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

Windgap Medical Inc. is a biotechnology company that specializes in the manufacture of compact epinephrine autoinjectors designed for the treatment of anaphylaxis, a severe allergic reaction. Established in 2011, the company is headquartered in Watertown, Massachusetts. Windgap Medical's innovative auto-injectors are filled with heat-stable epinephrine, which enhances the temperature resilience and shelf life of the medication. This feature allows healthcare providers to effectively administer epinephrine to patients experiencing acute allergy attacks, improving their chances of recovery during critical moments.

TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates. Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.

MANA Therapeutics develops innovative cell therapies aimed at providing safe and durable treatments for cancer. The company focuses on harnessing the power of immune cells to combat cancer, with the goal of conferring long-lasting immunity to the disease. By educating endogenous immune cells, MANA Therapeutics enables clinicians to enhance the body’s natural defenses against cancer cells. Their approach not only seeks to eliminate cancer but also emphasizes economic viability, making these therapies accessible and sustainable in the long term. The team comprises dedicated scientists, physicians, and advocates committed to advancing cancer treatment through cutting-edge immune cell education techniques.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, established in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its primary compound, ricolinostat, is an oral, selective inhibitor of the enzyme HDAC6, aimed at restoring normal nerve function rather than merely managing pain and symptoms. Currently positioned to enter Phase 2 clinical trials, ricolinostat shows promise for treating various forms of peripheral neuropathy, including diabetic, chemotherapy-induced, and inherited types, supported by preclinical studies that demonstrate its ability to regenerate normal protein function. Additionally, the company is exploring the potential applications of ricolinostat in treating sickle cell disease and beta-thalassemia.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

MANA Therapeutics develops innovative cell therapies aimed at providing safe and durable treatments for cancer. The company focuses on harnessing the power of immune cells to combat cancer, with the goal of conferring long-lasting immunity to the disease. By educating endogenous immune cells, MANA Therapeutics enables clinicians to enhance the body’s natural defenses against cancer cells. Their approach not only seeks to eliminate cancer but also emphasizes economic viability, making these therapies accessible and sustainable in the long term. The team comprises dedicated scientists, physicians, and advocates committed to advancing cancer treatment through cutting-edge immune cell education techniques.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

Acetylon Pharmaceuticals, Inc. is focused on developing small molecule drugs that target epigenetic mechanisms to improve therapeutic outcomes in cancer and other serious diseases. Established in 2008 and headquartered in Boston, Massachusetts, the company has created a proprietary platform that has led to a portfolio of optimized selective compounds for oral administration, specifically targeting Class I and Class II histone deacetylases. Among its lead drug candidates are ACY-1215 and ACY-241, which are selective HDAC6 inhibitors currently undergoing Phase 2 and Phase 1b clinical trials for the treatment of multiple myeloma. Acetylon Pharmaceuticals operates as a subsidiary of Celgene Corporation, emphasizing its commitment to addressing critical unmet medical needs through innovative epigenetic therapies.

OPNET Technologies, Inc., founded in 1986, specializes in software products and services designed for managing networks and applications. The company distinguishes itself by emphasizing analytics, which enable users to analyze collected data and transform it into actionable insights. Unlike traditional network management systems that primarily focus on data collection and monitoring historical trends, OPNET's solutions facilitate the rapid resolution of performance issues and proactively prevent potential problems. These issues may include network configuration errors, congestion, and inefficiencies between the network and applications. By providing advanced analytical capabilities, OPNET aims to enhance the performance and availability of critical networks and applications, ensuring that organizations can effectively manage their technology infrastructure.